NewcelX (NCEL) highlights strategic Eledon collaboration on NCEL-101 for Type 1 diabetes

Rhea-AI Filing Summary

NewcelX Ltd. filed a current report describing that it has issued a press release announcing a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program targeting Type 1 diabetes. The report also states that the first four paragraphs of this press release are incorporated by reference into several existing NewcelX shelf registration statements on Form F-3.

Insights

Biotech collaboration analyst

NewcelX flags a strategic collaboration on NCEL-101 via a brief cross‑referenced filing.

NewcelX Ltd. highlights a strategic collaboration with Eledon Pharmaceuticals focused on its NCEL-101 program for Type 1 diabetes. The filing itself is short and mainly points investors to the accompanying press release for substantive details of the arrangement.

The first four paragraphs of that release are incorporated by reference into multiple NewcelX Form F-3 registration statements. This linkage means the collaboration description now forms part of the company’s core offering documents, but concrete economic terms or development milestones are not described in this excerpt.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2026 (Report No. 1)

Commission File Number: 001-39957

NEWCELX LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F       ☐ Form 40-F

CONTENTS

On March 9, 2026, NewcelX Ltd., a corporation incorporated under the laws of Switzerland, issued a press release titled: “NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) to Advance NCEL-101 Program for Type 1 Diabetes.” A copy of this press release is furnished herewith as Exhibit 99.1.

The first four paragraphs of the press release attached hereto as Exhibit 99.1 are incorporated by reference into the registrant’s Registration Statements on Form F-3 (File Nos. 333-284696, 333-284811, 333-282788, 333-262489, 333-268690 and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) to Advance NCEL-101 Program for Type 1 Diabetes.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NewcelX Ltd.
Date: March 9, 2026	By:	/s/ Ronen Twito
		Name:	Ronen Twito
		Title:	Chief Executive Officer

3

FAQ

What did NewcelX (NCEL) report in its latest Form 6-K?

NewcelX reported that it issued a press release announcing a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program for Type 1 diabetes. The filing primarily serves to furnish and reference that press release.

Which program is covered by NewcelX’s collaboration with Eledon Pharmaceuticals?

The collaboration focuses on NewcelX’s NCEL-101 program for Type 1 diabetes. The Form 6-K states only the program name and disease area, directing readers to the attached press release for additional background and context.

How is the NewcelX NCEL-101 collaboration disclosure used in its F-3 registrations?

NewcelX incorporates the first four paragraphs of the NCEL-101 collaboration press release into several Form F-3 registration statements. This makes that descriptive content part of the company’s registered offering documents, unless superseded by later filings.

Who is NewcelX’s partner in the NCEL-101 Type 1 diabetes collaboration?

NewcelX’s partner is Eledon Pharmaceuticals, identified with the Nasdaq symbol ELDN. The Form 6-K describes the arrangement as a strategic collaboration, with further information furnished in the attached Exhibit 99.1 press release.

Does the NewcelX Form 6-K include financial terms of the Eledon collaboration?

The excerpted Form 6-K does not detail any financial or commercial terms of the collaboration. It primarily records that a press release was issued and formally incorporates portions of that release into existing Form F-3 registration statements.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "NEWCELX ANNOUNCES STRATEGIC COLLABORATION WITH ELEDON PHA 11.5 KB